TLR3 and cancer: This two component RNA vaccine (mRNA to mediate antigen expression in situ and non-coding dsRNA to stimulate the innate immune system via TLR3) is efficacious in animal models of influenza and cancer (47), and has been shown to be safe and immunogenic as a cancer vaccine strategy in humans (48).